Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.92 EUR | +0.75% | +2.20% | -21.81% |
Apr. 25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.81% | 837M | |
+31.63% | 49.46B | |
+1.69% | 42.58B | |
+49.11% | 42.49B | |
-5.26% | 29.09B | |
+12.63% | 26.61B | |
-23.76% | 18.64B | |
+8.02% | 13.16B | |
+30.74% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- FYB Stock
- News Formycon AG
- Formycon Wins Regulatory Nod for Lucentis Biosimilar in Saudi Arabia